Pharmaceuticals
Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection
--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far --Dosage of 800 mg ASC10, twice daily was selected to conduct a Phase IIa study in patients with RSV infection --Preclinical research showed t...
2023-01-31 17:40
4488
Delivery of 170,000 Bottles of Azvudine Tablets During Spring Festival to Help Rural Areas Weather the Epidemic
HONG KONG, Jan. 31, 2023 /PRNewswire/ -- In response to the infection peak season of COVID-19 in rural areas that may be brought about by people returning home during Chinese New Year, Fosun Foundation announced on9 January 2023 the cooperation with Fosun Pharma and Genuine Biotech to donateRMB10...
2023-01-31 16:10
4484
Daewoong enters exclusive licensing agreement with CS Pharmaceuticals for Bersiporocin in Idiopathic Pulmonary Fibrosis in the Greater China Region
* Daewoong Pharmaceutical to receive up to $76M upfront and development milestone payment plus a double-digit royalties on Net Sales * CS Pharmaceuticals will receive exclusive rights for development and commercialization of Bersiporocin for the treatment of IPF and other respiratory indica...
2023-01-31 14:43
6000
Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 3 Clinical Trials of Ecnoglutide (XW003), a Long-acting GLP-1 analog, for the Treatment of Type 2 Diabetes in China
HANGZHOU, China and SAN FRANCISCO, Jan. 31, 2023 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today the initiation of patient dosing in Phase 3 clinical tr...
2023-01-31 08:00
3815
Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
* ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers. * ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat. * ORSERDU is the first endocrine innovation in more than 20 years, specif...
2023-01-30 20:39
3572
Kalbe Consumer Health Crowned Winner at the Asia Pacific Enterprise Awards 2022 Regional Edition
SINGAPORE, Jan. 27, 2023 /PRNewswire/ -- Enterprise Asia, the organizer of the Asia Pacific Enterprise Awards (APEA) 2022 Regional Edition, is pleased to recognize 25 exemplary business leaders and enterprises acrossAsia which excelled and showcased unparalleled resilience and growth despite theC...
2023-01-30 11:26
3275
Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib（ABSK021）
SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that its CSF-1R inhibitor Pimicotinib（ABSK021）has been granted the breakthrough therapy designation from FDA for the treatment of tenosynovial giant cell tumor (TGCT) patients...
2023-01-30 11:00
5714
Malaysian Society of Plastic and Reconstructive Surgery to host extensive networking and learning event for plastic surgeons and residents
The two-day symposium will have its core focus on cosmetic breast surgery, with two live surgical demonstrations. CPD points to be given to all participating surgeons. KUALA LUMPUR, Malaysia, Jan. 27, 2023 /PRNewswire/ -- The Malaysian Society for Plastic and Reconstructive Surgery (MSPRS) is s...
2023-01-27 08:00
5008
Fosun International Wins Platinum Award at The Asset ESG Corporate Awards 2022
HONG KONG, Jan. 26, 2023 /PRNewswire/ -- Fosun International Limited ("Fosun International" or the "Company") (HKEX: 00656) was informed byThe Asset, the renowned international asset management and investment magazine, that Fosun has garnered the Platinum Award at The Asset ESG Corporate Awards 2...
2023-01-26 14:59
5080
Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue in 11 countries, only 1 year after approval in Korea
"Expected to change GERD drug market landscape" * Application for product approval of Fexuclue, a new drug for gastroesophageal reflux disease (GERD), has been completely submitted toColombia ,Vietnam, and Saudi Arabia * NDA submissions in 11 countries completed in the shortest time among K...
2023-01-26 09:14
3775
Malaysia Healthcare Partners with AirAsia
Cambodian Passengers Can Kickstart 2023 with Wellness Travel to Malaysia PHNOM PENH, Cambodia, Jan. 25, 2023 /PRNewswire/ -- In its pursuit to providing accessible preventive healthcare and wellness options for global citizens, Malaysia Healthcare Travel Council (MHTC) partners with AirAsia, off...
2023-01-25 14:05
4905
A Healthy Winter Action: Second Batch of 19,600 Bottles of Azvudine Delivered to 24 Counties
COVID-19 Prevention and Treatment Live-Streaming Training for Rural Doctors Attracted over 1 Million Views HONG KONG, Jan. 20, 2023 /PRNewswire/ -- On January 16, the second stage of "A Healthy Winter Action" initiated by Fosun Foundation in conjunction with other institutions kicked off, with 1...
2023-01-20 18:12
5913
Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global De...
2023-01-19 23:05
6831
Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications
ROCKVILLE, Md. and SUZHOU, China, Jan. 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...
2023-01-18 21:34
4838
Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster
GAITHERSBURG, Md., Jan. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that partner SK bioscience has received expanded manufacturing and marketing...
2023-01-18 21:00
4229
Cambrex Completes Acquisition of Snapdragon Chemistry, a Leader in Continuous Flow API Development Services
EAST RUTHERFORD, N.J., Jan. 18, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that it has completed its acquisition of Snap...
2023-01-18 19:00
3836
Docquity delivers 10% market share growth for Philippine-based pharmaceutical client in just one year
* Docquity's leading network of HCPs and proprietary Awareness to Advocacy (A2A) solution complemented the Client's Sales and Marketing team to increase conversions in a highly competitive pain product market * Client was able to grow prescriptions and revenue, with over 80% cost savings comp...
2023-01-18 10:00
5020
Boehringer Ingelheim Malaysia Honored As Top Employer For The Fifth Consecutive Year
* Boehringer Ingelheim is one of 15 global Top Employers worldwide * Achieved Global Recognition and Top Employer Certification in 29 countries From Top Employers Institute® * Outstanding employer benefits with emphasis on wellbeing, attractive work environment, and rewards and recognition...
2023-01-18 09:00
3476
Boehringer Ingelheim Vietnam Honored As Top Employer For The Fourth Consecutive Year
HO CHI MINH CITY, Vietnam, Jan. 18, 2023 /PRNewswire/ -- Boehringer Ingelheim Vietnam has been honored for the fourth year in succession for its outstanding employee benefits with emphasis on wellbeing, attractive work environment, and rewards and recognition. Globally, Boehringer Ingelheim has ...
2023-01-18 09:00
4381
Telix Reports Fourth Quarter 2022 Financial Results
MELBOURNE, Australia, Jan. 18, 2023 /PRNewswire/ -- 18 January 2023. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended31 December 2022 (Q4 2022). All figures are in AUD$ ...
2023-01-18 08:50
3981
Week's Top Stories
Most Reposted
Futurise Impact Report 2025 Highlights Progress in Regulatory Innovation Future-Ready Technologies
[Picked up by 272 media titles]
2026-09-09 13:26
Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00New ASEAN Study Reveals Businesses Are Rethinking Hiring and Investment as Growth Priorities Shift
[Picked up by 260 media titles]
2026-09-10 07:45
AKSADRON Releases Impact Report 2025, Showcasing the Growth of Malaysia's Drone Sports Talent Ecosystem
[Picked up by 255 media titles]
2026-09-14 15:36
Qunabox Group Opens '99 Quna Festival,' Debuting Consumer-Facing Physical AI Entertainment
[Picked up by 251 media titles]
2026-09-09 11:01Most Read
ALLSWIFIT Introduces ActiveRise+, a Stable Carbon-Plate Running Shoe Built to Help Everyday Runners Train Smarter and Run Stronger
2026-09-11 21:00
10257
